Clinical Trials · NCT07101939
A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2)
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- Actimed Therapeutics Ltd
- Enrollment
- 120
- Start date
- Jun 2025
- Locations
- 7 sites, Serbia
- Primary endpoint
- The change in lean body mass (LBM) in patients receiving one of two doses of ACM-001.1 whilst also receiving semaglutide.